Press Releases

 
Press Releases
  Date Title View
Nov 9, 2017
LEXINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced financial results for the quarter ended September 30,...
PDF
Nov 7, 2017
LEXINGTON, Mass., Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of...
PDF
Nov 2, 2017
LEXINGTON, Mass., Nov. 2, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will issue financial results for the third quarter ended September 30...
PDF
Oct 25, 2017
LEXINGTON, Mass., Oct. 25, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present data from the previously announced Phase 2 clinical tri...
PDF
Oct 24, 2017
LEXINGTON, Mass., Oct. 24, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented novel data at the American Society of Human Genetics 2017 Annual Meeting demo...
PDF
Oct 10, 2017
LEXINGTON, Mass., Oct. 10, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, announced new clinical data for ADX-102 from recently completed Phas...
PDF
Oct 5, 2017
LEXINGTON, Mass., Oct. 5, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present novel data on the efficacy of ADX-102 in a model of Succ...
PDF
Sep 27, 2017
LEXINGTON, Mass., Sept. 27, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity today announced that it will host a Research and Development Day to discuss new clinica...
PDF
Sep 21, 2017
LEXINGTON, Mass., Sept. 21, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the closing of its previously announced underwritten public offering o...
PDF
Sep 20, 2017
LEXINGTON, Mass., Sept. 20, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will pre...
PDF
Page:
1
... NextLast